A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma

Trial Profile

A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CRS 207 (Primary) ; Pembrolizumab
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 28 Jun 2017 According to an Aduro BioTech media release, first patients has been dosed.
    • 02 Jun 2017 Status changed from planning to recruiting.
    • 17 May 2017 According to an Aduro BioTech media release, this trial will be conducted by Aduro BioTech in collaboration with Merck.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top